Investing.comCodex · 实盘不做把握 5/10
北京时间·🕒 发布 02:40:34时区推断·⟳ 抓取 02:42:31·⚡ 决策 07-23 02:51:41 +9m10s·96.6 天前
Penumbra THUNDER研究达到87.5%再灌注目标但关键获批已是旧催化
THUNDER研究216例、29个美国中心，Thunderbolt术后87.5%达到mTICI 2b-3，安全性数据较好，对产品临床验证为正面。
📄 原文Investing.com↗ 原文
Penumbra’s Thunderbolt stroke device meets study goals
Wall Street makes small moves ahead of closely-watched tech earnings for AI cues ALAMEDA, Calif. - Penumbra Inc. (NYSE:…
不做 Penumbra（PEN.US）
THUNDER数据正面但监管获批和CE Mark已在6月公开，未披露新增销售或业绩量级，且公司股价受收购交易背景约束，当前无独立短线edge。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- FDA对Penumbra System Thunderbolt Aspiration Tubing作出Substantially Equivalent决定，510(k)号K250690。
- 公司宣布Thunderbolt获得美国FDA clearance，用于急性缺血性卒中CAVT。
- 公司披露Thunderbolt获得欧洲CE Mark，海外准入也已提前公开。
- 媒体转述THUNDER研究达到预设目标，属临床会议数据更新。
关键理由
- THUNDER研究216例、29个美国中心，Thunderbolt术后87.5%达到mTICI 2b-3，安全性数据较好，对产品临床验证为正面。
- 但Thunderbolt的美国FDA clearance在2026年6月10日已作出、公司6月11日已发布，CE Mark也在6月中旬披露，本条更多是会议数据更新而非首次商业化准入。
- 公司层面还存在Boston Scientific拟以约145亿美元收购Penumbra的交易背景，股价短线更受交易对价/监管进展约束，单个会议数据难以形成独立重定价。
主要风险
- 本条未披露新增订单、销售指引或收入增量，无法量化短期业绩贡献。
- 核心FDA获批信息已提前一个多月公开，会议数据可能被视为确认而非新增催化。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-06-11 · 影响 weakens
关键监管获批已提前一个多月公开，本条只是研究数据更新，削弱短线追多edge。
检索:Penumbra Thunderbolt FDA clearance CE Mark Thunderbolt thrombectomy system commercial launch 原文 ↗ - 做多前查反向 · 来源 web · 日期 2026-02-25 · 影响 weakens
Penumbra公告列表显示Boston Scientific收购Penumbra交易已是重要公司事件，可能压低单品数据对股价的独立影响。
检索:Penumbra Boston Scientific acquisition January 2026 14.5B 原文 ↗
原文全文
展开原文 · 1,911 字
Wall Street makes small moves ahead of closely-watched tech earnings for AI cues
ALAMEDA, Calif. - Penumbra Inc. (NYSE:PEN) announced results from its THUNDER study evaluating the Thunderbolt computer assisted vacuum thrombectomy system for treating stroke patients with emergent large vessel occlusion, according to a press release statement issued today.
The study met its predefined performance goal with 87.5% of cases achieving successful reperfusion, defined as mTICI 2b-3, after treatment with Thunderbolt. The data were presented this week at the Society of NeuroInterventional Surgery 23rd Annual Meeting.
The THUNDER study enrolled 216 patients across 29 U.S. centers in a single-arm, prospective, multicenter trial with core-lab adjudication. First-pass mTICI 2b-3 was achieved in 64.8% of cases, while mTICI 2c-3 was achieved 70.4% of the time post-treatment. Median time-to-revascularization was 20 minutes.
Complete clot ingestion occurred in 83% of cases. Device or procedure-related serious adverse events occurred in 2.8% of cases, symptomatic intracranial hemorrhage in 0.9%, and all-cause mortality at 90 days was 11.7%.
"The THUNDER study demonstrated a high rate of complete clot ingestion with Thunderbolt, along with a low rate of complications," said Donald Frei, co-principal investigator of THUNDER and neurointerventional radiologist at Swedish Medical Center in Denver.
Thunderbolt recently received U.S. FDA clearance and CE Mark. The device uses modulated aspiration technology designed to detect, fatigue and ingest clots at the site of occlusion.
Acute ischemic stroke accounts for approximately 87% of all strokes and affects an estimated 68 million people worldwide. Approximately 20% to 42% of acute ischemic stroke cases are due to emergent large vessel occlusion.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
ALAMEDA, Calif. - Penumbra Inc. (NYSE:PEN) announced results from its THUNDER study evaluating the Thunderbolt computer assisted vacuum thrombectomy system for treating stroke patients with emergent large vessel occlusion, according to a press release statement issued today.
The study met its predefined performance goal with 87.5% of cases achieving successful reperfusion, defined as mTICI 2b-3, after treatment with Thunderbolt. The data were presented this week at the Society of NeuroInterventional Surgery 23rd Annual Meeting.
The THUNDER study enrolled 216 patients across 29 U.S. centers in a single-arm, prospective, multicenter trial with core-lab adjudication. First-pass mTICI 2b-3 was achieved in 64.8% of cases, while mTICI 2c-3 was achieved 70.4% of the time post-treatment. Median time-to-revascularization was 20 minutes.
Complete clot ingestion occurred in 83% of cases. Device or procedure-related serious adverse events occurred in 2.8% of cases, symptomatic intracranial hemorrhage in 0.9%, and all-cause mortality at 90 days was 11.7%.
"The THUNDER study demonstrated a high rate of complete clot ingestion with Thunderbolt, along with a low rate of complications," said Donald Frei, co-principal investigator of THUNDER and neurointerventional radiologist at Swedish Medical Center in Denver.
Thunderbolt recently received U.S. FDA clearance and CE Mark. The device uses modulated aspiration technology designed to detect, fatigue and ingest clots at the site of occlusion.
Acute ischemic stroke accounts for approximately 87% of all strokes and affects an estimated 68 million people worldwide. Approximately 20% to 42% of acute ischemic stroke cases are due to emergent large vessel occlusion.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。